| 3.21 0.17 (5.59%) | 11-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Mon, 27 Oct 2025
Qualigen Therapeutics to Rebrand as AIxCrypto After - GlobeNewswire
Thu, 23 Oct 2025
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation - Yahoo Finance
Mon, 13 Oct 2025
Qualigen Therapeutics, Inc. (QLGN) Stock: Poised for Rebound as CXC10 Launches Crypto Asset Treasury Amid Market Turmoil - parameter.io
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|